Ligand Pharma (LGND) Tops Q1 EPS by 36c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $316.13 +0.83%
Financial Fact:
Collaborative research and development and other revenues: 1.7M
Today's EPS Names:
COHR, ATS, SICP, More
Financial Fact:
Collaborative research and development and other revenues: 1.7M
Today's EPS Names:
COHR, ATS, SICP, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.20, $0.36 better than the analyst estimate of $0.84. Revenue for the quarter came in at $30.98 million versus the consensus estimate of $26.69 million.
GUIDANCE:
Ligand Pharma sees FY2024 EPS of $4.25-$4.75, versus the consensus of $4.44. Ligand Pharma sees FY2024 revenue of $130-142 million, versus the consensus of $137.3 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Vertex (VERX) Tops Q3 EPS by 4c; Offers Guidance
- Eversource Energy (ES) Tops Q3 EPS by 18c; offers guidance
- Personalis, Inc. (PSNL) Misses Q3 EPS by 6c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
